Celon Pharma says generic semaglutide matched Ozempic in early study
Shares in the Polish drugmaker jumped on the company's report of comparability data, Reuters said.
The wire
- 01Celon Pharma reported that its generic semaglutide matched Ozempic in an early-stage study, and its shares rose on the news.
- 02Generic and biosimilar semaglutide entrants matter for pharmacies and telehealth operators planning post-exclusivity supply and pricing.
- 03Details of the study design, endpoints and regulatory path were not given in the report; the findings are the company's own early-stage data.
From the source
Read at reuters.comCelon Pharma's generic semaglutide drug matches Ozempic in early study, shares jump